Parkinson's disease and pregnancy

An updated review

Mara D Seier, Amie Hiller

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Pregnancy does not often occur in the setting of Parkinson's disease (PD) as the most common age of onset is beyond the childbearing years, yet management of these two conditions is crucial for the health of both mother and child. Here we review treatment data of PD during pregnancy, primarily from case reports and drug registries, and focus on available evidence regarding the pregnancy risks for patient and fetus. Historically, it was reported that many women had worsening of symptoms during pregnancy but this may be because anti-parkinsonian medications were not recommended or were under dosed. Levodopa has the best safety data for use in pregnancy and amantadine should be avoided in women who are pregnant or trying to become pregnant. The data for other pharmacological and surgical treatments is less clear. There is no evidence that women with PD have higher rates of birth or fetal complications.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalParkinsonism and Related Disorders
Volume40
DOIs
StatePublished - Jul 1 2017

Fingerprint

Parkinson Disease
Pregnancy
Amantadine
Birth Rate
Levodopa
Age of Onset
Registries
Pregnant Women
Fetus
Mothers
Pharmacology
Safety
Health
Therapeutics
Pharmaceutical Preparations

Keywords

  • Levodopa
  • Parkinson's disease
  • Pregnancy
  • Women

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Parkinson's disease and pregnancy : An updated review. / Seier, Mara D; Hiller, Amie.

In: Parkinsonism and Related Disorders, Vol. 40, 01.07.2017, p. 11-17.

Research output: Contribution to journalReview article

@article{8789384599044b9fa27fccf41d990bce,
title = "Parkinson's disease and pregnancy: An updated review",
abstract = "Pregnancy does not often occur in the setting of Parkinson's disease (PD) as the most common age of onset is beyond the childbearing years, yet management of these two conditions is crucial for the health of both mother and child. Here we review treatment data of PD during pregnancy, primarily from case reports and drug registries, and focus on available evidence regarding the pregnancy risks for patient and fetus. Historically, it was reported that many women had worsening of symptoms during pregnancy but this may be because anti-parkinsonian medications were not recommended or were under dosed. Levodopa has the best safety data for use in pregnancy and amantadine should be avoided in women who are pregnant or trying to become pregnant. The data for other pharmacological and surgical treatments is less clear. There is no evidence that women with PD have higher rates of birth or fetal complications.",
keywords = "Levodopa, Parkinson's disease, Pregnancy, Women",
author = "Seier, {Mara D} and Amie Hiller",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.parkreldis.2017.05.007",
language = "English (US)",
volume = "40",
pages = "11--17",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Parkinson's disease and pregnancy

T2 - An updated review

AU - Seier, Mara D

AU - Hiller, Amie

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Pregnancy does not often occur in the setting of Parkinson's disease (PD) as the most common age of onset is beyond the childbearing years, yet management of these two conditions is crucial for the health of both mother and child. Here we review treatment data of PD during pregnancy, primarily from case reports and drug registries, and focus on available evidence regarding the pregnancy risks for patient and fetus. Historically, it was reported that many women had worsening of symptoms during pregnancy but this may be because anti-parkinsonian medications were not recommended or were under dosed. Levodopa has the best safety data for use in pregnancy and amantadine should be avoided in women who are pregnant or trying to become pregnant. The data for other pharmacological and surgical treatments is less clear. There is no evidence that women with PD have higher rates of birth or fetal complications.

AB - Pregnancy does not often occur in the setting of Parkinson's disease (PD) as the most common age of onset is beyond the childbearing years, yet management of these two conditions is crucial for the health of both mother and child. Here we review treatment data of PD during pregnancy, primarily from case reports and drug registries, and focus on available evidence regarding the pregnancy risks for patient and fetus. Historically, it was reported that many women had worsening of symptoms during pregnancy but this may be because anti-parkinsonian medications were not recommended or were under dosed. Levodopa has the best safety data for use in pregnancy and amantadine should be avoided in women who are pregnant or trying to become pregnant. The data for other pharmacological and surgical treatments is less clear. There is no evidence that women with PD have higher rates of birth or fetal complications.

KW - Levodopa

KW - Parkinson's disease

KW - Pregnancy

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85019197452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019197452&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2017.05.007

DO - 10.1016/j.parkreldis.2017.05.007

M3 - Review article

VL - 40

SP - 11

EP - 17

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -